Structure Therapeutics Inc. Debt Securities Available For Sale Excluding Accrued Interest
Structure Therapeutics Inc. (GPCR) had Debt Securities Available For Sale Excluding Accrued Interest of $1.34 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets
us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest · last filed 2026-08-06
- 2026-06-30: Debt Securities Available For Sale Excluding Accrued Interest $1.34B.
- 2026-03-31: Debt Securities Available For Sale Excluding Accrued Interest $1.45B.
- 2025-12-31: Debt Securities Available For Sale Excluding Accrued Interest $1.44B.
- 2025-09-30: Debt Securities Available For Sale Excluding Accrued Interest $791.55M.
| Period end | Debt Securities Available For Sale Excluding Accrued Interest |
|---|---|
| 2026-06-30 | $1.34B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.45B 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.44B 10-Q · filed 2026-08-06 |
| 2025-09-30 | $791.55M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $778.53M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $823.93M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $875.34M 10-K · filed 2026-02-26 |
| 2024-09-30 | $905.07M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $918.34M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $427.24M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $461.97M 10-K · filed 2025-02-27 |
| 2022-12-31 | $83.74M 10-K · filed 2024-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |